Literature DB >> 19148798

Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials.

Hideki Ishikawa1, Tomiyo Nakamura, Atsuko Kawano, Nobuhisa Gondo, Toshiyuki Sakai.   

Abstract

The rapidly increasing incidence of colorectal cancer in Japan poses a great challenge to researchers to develop preventive strategies against this disease. Thus far, several clinical trials for this purpose have been planned in Japanese subjects; some have been completed and documented while others are still ongoing. Also, the Ministry of Health, Labour and Welfare of Japan recognizes the significance of cancer prevention studies, especially against colorectal cancer, including it as one of the pillars in the "Third Research Project on General Strategies against Cancer" and funding several large-scale projects. Among them are two chemoprevention studies currently being performed: in patients with previous sporadic colorectal tumors (J-CAPP study) and in patients with familial adenomatous polyposis (J-FAPP study II). Both are double-blind randomized controlled trials with low-dose aspirin (100 mg/day), which is generally considered to be safe for long-term use. This article outlines relevant past clinical data and gives a brief introduction to these two studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148798     DOI: 10.1007/s00535-008-2286-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

1.  Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

Review 2.  DNA methylation as a marker for the past and future.

Authors:  Toshikazu Ushijima; Takeshi Nakajima; Takao Maekita
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

3.  Adverse effects of sulindac used for prevention of colorectal cancer.

Authors:  H Ishikawa; I Akedo; T Suzuki; H Narahara; T Otani
Journal:  J Natl Cancer Inst       Date:  1997-09-17       Impact factor: 13.506

4.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

5.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Authors:  Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

Review 6.  Colorectal cancer: genetics of development and metastasis.

Authors:  Tetsuji Takayama; Koji Miyanishi; Tsuyoshi Hayashi; Yasushi Sato; Yoshiro Niitsu
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

7.  Sulindac causes regression of rectal polyps in familial adenomatous polyposis.

Authors:  D Labayle; D Fischer; P Vielh; F Drouhin; A Pariente; C Bories; O Duhamel; M Trousset; P Attali
Journal:  Gastroenterology       Date:  1991-09       Impact factor: 22.682

8.  Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules.

Authors:  I Akedo; H Ishikawa; T Nakamura; K Kimura; I Takeyama; T Suzuki; M Kameyama; S Sato; T Nakamura; Y Matsuzawa; T Kakizoe; T Otani
Journal:  Jpn J Clin Oncol       Date:  1998-12       Impact factor: 3.019

9.  Sulindac for polyposis of the colon.

Authors:  W R Waddell; R W Loughry
Journal:  J Surg Oncol       Date:  1983-09       Impact factor: 3.454

10.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

View more
  5 in total

Review 1.  Aspirin, cyclooxygenase inhibition and colorectal cancer.

Authors:  Carlos Sostres; Carla Jerusalen Gargallo; Angel Lanas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

Review 2.  Aspirin for the prevention of colorectal cancer.

Authors:  X Garcia-Albeniz; A T Chan
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 3.  Aspirin in the chemoprevention of colorectal neoplasia: an overview.

Authors:  Andrew T Chan; Nadir Arber; John Burn; Whay Kuang Chia; Peter Elwood; Mark A Hull; Richard F Logan; Peter M Rothwell; Karsten Schrör; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2011-11-14

4.  Aspirin and familial adenomatous polyposis: coming full circle.

Authors:  Andrew T Chan
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

5.  Mechanistic and pharmacological issues of aspirin as an anticancer agent.

Authors:  Melania Dovizio; Stefania Tacconelli; Carlos Sostres; Emanuela Ricciotti; Paola Patrignani
Journal:  Pharmaceuticals (Basel)       Date:  2012-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.